The cost of persistent Asthma in Europe: An international population-based study in adults therapy and health economics working group of the european community respiratory health survey II

Simone Accordini, Angelo G. Corsico, Marco Braggion, Margaret W. Gerbase, David Gislason, Amund Gulsvik, Joachim Heinrich, Christer Janson, Deborah Jarvis, Rain Jõgi, Isabelle Pin, Yvonne Schoefer, Massimiliano Bugiani, Lucia Cazzoletti, Isa Cerveri, Alessandro Marcon, Roberto De Marco

Research output: Contribution to journalArticle

Abstract

Background: This study is aimed at providing a real-world evaluation of the economic cost of persistent asthma among European adults according to the degree of disease control [as defined by the 2006 Global Initiative for Asthma (GINA) guidelines]. Methods: A prevalence-based cost-of-illness study was carried out on 462 patients aged 30-54 years with persistent asthma (according to the 2002 GINA definition), who were identified in general population samples from 11 European countries and examined in clinical settings in the European Community Respiratory Health Survey II between 1999 and 2002. The cost estimates were computed from the societal perspective following the bottom-up approach on the basis of rates, wages and prices in 2004 (obtained at the national level from official sources), and were then converted to the 2010 values. Results: The mean total cost per patient was EUR 1,583 and was largely driven by indirect costs (i.e. lost working days and days with limited, not work-related activities 62.5%). The expected total cost in the population aged 30-54 years of the 11 European countries was EUR 4.3 billion (EUR 19.3 billion when extended to the whole European population aged from 15 to 64 years). The mean total cost per patient ranged from EUR 509 (controlled asthma) to EUR 2,281 (uncontrolled disease). Chronic cough or phlegm and having a high BMI significantly increased the individual total cost. Conclusions: Among European adults, the cost of persistent asthma drastically increases as disease control decreases. Therefore, substantial cost savings could be obtained through the proper management of adult patients in Europe.

Original languageEnglish
Pages (from-to)93-101
Number of pages9
JournalInternational Archives of Allergy and Immunology
Volume160
Issue number1
DOIs
Publication statusPublished - Dec 2012

Fingerprint

European Union
Health Surveys
Asthma
Economics
Costs and Cost Analysis
Health
Population
Therapeutics
Cost of Illness
Cost Savings
Salaries and Fringe Benefits
Cough
Cost-Benefit Analysis
Guidelines

Keywords

  • Asthma
  • Cost of illness
  • Disease control

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

The cost of persistent Asthma in Europe : An international population-based study in adults therapy and health economics working group of the european community respiratory health survey II. / Accordini, Simone; Corsico, Angelo G.; Braggion, Marco; Gerbase, Margaret W.; Gislason, David; Gulsvik, Amund; Heinrich, Joachim; Janson, Christer; Jarvis, Deborah; Jõgi, Rain; Pin, Isabelle; Schoefer, Yvonne; Bugiani, Massimiliano; Cazzoletti, Lucia; Cerveri, Isa; Marcon, Alessandro; De Marco, Roberto.

In: International Archives of Allergy and Immunology, Vol. 160, No. 1, 12.2012, p. 93-101.

Research output: Contribution to journalArticle

Accordini, S, Corsico, AG, Braggion, M, Gerbase, MW, Gislason, D, Gulsvik, A, Heinrich, J, Janson, C, Jarvis, D, Jõgi, R, Pin, I, Schoefer, Y, Bugiani, M, Cazzoletti, L, Cerveri, I, Marcon, A & De Marco, R 2012, 'The cost of persistent Asthma in Europe: An international population-based study in adults therapy and health economics working group of the european community respiratory health survey II', International Archives of Allergy and Immunology, vol. 160, no. 1, pp. 93-101. https://doi.org/10.1159/000338998
Accordini, Simone ; Corsico, Angelo G. ; Braggion, Marco ; Gerbase, Margaret W. ; Gislason, David ; Gulsvik, Amund ; Heinrich, Joachim ; Janson, Christer ; Jarvis, Deborah ; Jõgi, Rain ; Pin, Isabelle ; Schoefer, Yvonne ; Bugiani, Massimiliano ; Cazzoletti, Lucia ; Cerveri, Isa ; Marcon, Alessandro ; De Marco, Roberto. / The cost of persistent Asthma in Europe : An international population-based study in adults therapy and health economics working group of the european community respiratory health survey II. In: International Archives of Allergy and Immunology. 2012 ; Vol. 160, No. 1. pp. 93-101.
@article{29fdec621c1942029f12333582fe8fe3,
title = "The cost of persistent Asthma in Europe: An international population-based study in adults therapy and health economics working group of the european community respiratory health survey II",
abstract = "Background: This study is aimed at providing a real-world evaluation of the economic cost of persistent asthma among European adults according to the degree of disease control [as defined by the 2006 Global Initiative for Asthma (GINA) guidelines]. Methods: A prevalence-based cost-of-illness study was carried out on 462 patients aged 30-54 years with persistent asthma (according to the 2002 GINA definition), who were identified in general population samples from 11 European countries and examined in clinical settings in the European Community Respiratory Health Survey II between 1999 and 2002. The cost estimates were computed from the societal perspective following the bottom-up approach on the basis of rates, wages and prices in 2004 (obtained at the national level from official sources), and were then converted to the 2010 values. Results: The mean total cost per patient was EUR 1,583 and was largely driven by indirect costs (i.e. lost working days and days with limited, not work-related activities 62.5{\%}). The expected total cost in the population aged 30-54 years of the 11 European countries was EUR 4.3 billion (EUR 19.3 billion when extended to the whole European population aged from 15 to 64 years). The mean total cost per patient ranged from EUR 509 (controlled asthma) to EUR 2,281 (uncontrolled disease). Chronic cough or phlegm and having a high BMI significantly increased the individual total cost. Conclusions: Among European adults, the cost of persistent asthma drastically increases as disease control decreases. Therefore, substantial cost savings could be obtained through the proper management of adult patients in Europe.",
keywords = "Asthma, Cost of illness, Disease control",
author = "Simone Accordini and Corsico, {Angelo G.} and Marco Braggion and Gerbase, {Margaret W.} and David Gislason and Amund Gulsvik and Joachim Heinrich and Christer Janson and Deborah Jarvis and Rain J{\~o}gi and Isabelle Pin and Yvonne Schoefer and Massimiliano Bugiani and Lucia Cazzoletti and Isa Cerveri and Alessandro Marcon and {De Marco}, Roberto",
year = "2012",
month = "12",
doi = "10.1159/000338998",
language = "English",
volume = "160",
pages = "93--101",
journal = "International Archives of Allergy and Immunology",
issn = "1018-2438",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - The cost of persistent Asthma in Europe

T2 - An international population-based study in adults therapy and health economics working group of the european community respiratory health survey II

AU - Accordini, Simone

AU - Corsico, Angelo G.

AU - Braggion, Marco

AU - Gerbase, Margaret W.

AU - Gislason, David

AU - Gulsvik, Amund

AU - Heinrich, Joachim

AU - Janson, Christer

AU - Jarvis, Deborah

AU - Jõgi, Rain

AU - Pin, Isabelle

AU - Schoefer, Yvonne

AU - Bugiani, Massimiliano

AU - Cazzoletti, Lucia

AU - Cerveri, Isa

AU - Marcon, Alessandro

AU - De Marco, Roberto

PY - 2012/12

Y1 - 2012/12

N2 - Background: This study is aimed at providing a real-world evaluation of the economic cost of persistent asthma among European adults according to the degree of disease control [as defined by the 2006 Global Initiative for Asthma (GINA) guidelines]. Methods: A prevalence-based cost-of-illness study was carried out on 462 patients aged 30-54 years with persistent asthma (according to the 2002 GINA definition), who were identified in general population samples from 11 European countries and examined in clinical settings in the European Community Respiratory Health Survey II between 1999 and 2002. The cost estimates were computed from the societal perspective following the bottom-up approach on the basis of rates, wages and prices in 2004 (obtained at the national level from official sources), and were then converted to the 2010 values. Results: The mean total cost per patient was EUR 1,583 and was largely driven by indirect costs (i.e. lost working days and days with limited, not work-related activities 62.5%). The expected total cost in the population aged 30-54 years of the 11 European countries was EUR 4.3 billion (EUR 19.3 billion when extended to the whole European population aged from 15 to 64 years). The mean total cost per patient ranged from EUR 509 (controlled asthma) to EUR 2,281 (uncontrolled disease). Chronic cough or phlegm and having a high BMI significantly increased the individual total cost. Conclusions: Among European adults, the cost of persistent asthma drastically increases as disease control decreases. Therefore, substantial cost savings could be obtained through the proper management of adult patients in Europe.

AB - Background: This study is aimed at providing a real-world evaluation of the economic cost of persistent asthma among European adults according to the degree of disease control [as defined by the 2006 Global Initiative for Asthma (GINA) guidelines]. Methods: A prevalence-based cost-of-illness study was carried out on 462 patients aged 30-54 years with persistent asthma (according to the 2002 GINA definition), who were identified in general population samples from 11 European countries and examined in clinical settings in the European Community Respiratory Health Survey II between 1999 and 2002. The cost estimates were computed from the societal perspective following the bottom-up approach on the basis of rates, wages and prices in 2004 (obtained at the national level from official sources), and were then converted to the 2010 values. Results: The mean total cost per patient was EUR 1,583 and was largely driven by indirect costs (i.e. lost working days and days with limited, not work-related activities 62.5%). The expected total cost in the population aged 30-54 years of the 11 European countries was EUR 4.3 billion (EUR 19.3 billion when extended to the whole European population aged from 15 to 64 years). The mean total cost per patient ranged from EUR 509 (controlled asthma) to EUR 2,281 (uncontrolled disease). Chronic cough or phlegm and having a high BMI significantly increased the individual total cost. Conclusions: Among European adults, the cost of persistent asthma drastically increases as disease control decreases. Therefore, substantial cost savings could be obtained through the proper management of adult patients in Europe.

KW - Asthma

KW - Cost of illness

KW - Disease control

UR - http://www.scopus.com/inward/record.url?scp=84865593053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865593053&partnerID=8YFLogxK

U2 - 10.1159/000338998

DO - 10.1159/000338998

M3 - Article

C2 - 22948386

AN - SCOPUS:84865593053

VL - 160

SP - 93

EP - 101

JO - International Archives of Allergy and Immunology

JF - International Archives of Allergy and Immunology

SN - 1018-2438

IS - 1

ER -